MedPath

Iovance Biotherapeutics

Iovance Biotherapeutics logo
๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
Public
Established
2007-01-01
Employees
557
Market Cap
$3.4B
Website
http://www.iovance.com
Introduction

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

Phase 2
Active, not recruiting
Conditions
Cervical Carcinoma
Interventions
First Posted Date
2017-04-11
Last Posted Date
2025-05-07
Lead Sponsor
Iovance Biotherapeutics, Inc.
Target Recruit Count
189
Registration Number
NCT03108495
Locations
๐Ÿ‡บ๐Ÿ‡ธ

LSU Health Sciences Center, New Orleans, Louisiana, United States

๐Ÿ‡บ๐Ÿ‡ธ

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 40 locations

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Phase 2
Completed
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Biological: LN-145
Biological: LN-145-S1
First Posted Date
2017-03-20
Last Posted Date
2023-10-12
Lead Sponsor
Iovance Biotherapeutics, Inc.
Target Recruit Count
64
Registration Number
NCT03083873
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Southern California, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Northwestern University, Chicago, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of California, Los Angeles, Los Angeles, California, United States

and more 19 locations

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

Phase 2
Completed
Conditions
Metastatic Melanoma
Interventions
First Posted Date
2015-02-10
Last Posted Date
2024-11-26
Lead Sponsor
Iovance Biotherapeutics, Inc.
Target Recruit Count
178
Registration Number
NCT02360579
Locations
๐Ÿ‡บ๐Ÿ‡ธ

The Angeles Clinic and Research Institute, Los Angeles, California, United States

๐Ÿ‡ฌ๐Ÿ‡ง

Royal Marsden NHS Trust, London, England, United Kingdom

๐Ÿ‡บ๐Ÿ‡ธ

Roswell Park Cancer Institute, Buffalo, New York, United States

and more 54 locations
ยฉ Copyright 2025. All Rights Reserved by MedPath